β-Nicotinamide mononucleotide, reduced form (disodium)

β-Nicotinamide mononucleotide, reduced form (NMNH) disodium is an orally active reduced version of β-Nicotinamide mononucleotide (HY-F0004) . β-Nicotinamide mononucleotide, reduced form disodium can significantly increase the levels of NAD+ and NADH, inhibit glycolysis, the tricarboxylic acid cycle, and cell growth, with its effects being dependent on nicotinamide mononucleotide adenylyltransferase (NMNAT) [1][2].

Product Specifications

CAS Number

[108347-85-9]

Product Name Alternative

NMNH (disodium)

UNSPSC

12352204

Hazard Statement

H302, H315, H319, H335

Target

Endogenous Metabolite

Type

Enzyme

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/β-nicotinamide-mononucleotide-reduced-form-disodium.html

Purity

99.55

Solubility

H2O : ≥ 100 mg/mL

Smiles

O[C@H]1[C@@H](O)[C@H](N2C=C(CC=C2)C(N)=O)O[C@@H]1COP(O[Na])(O[Na])=O

Molecular Formula

C11H15N2Na2O8P

Molecular Weight

380.20

Precautions

H302, H315, H319, H335

References & Citations

[1]Liu Y, et al. Reduced Nicotinamide Mononucleotide (NMNH) Potently Enhances NAD+ and Suppresses Glycolysis, the TCA Cycle, and Cell Growth. J Proteome Res. 2021 May 7;20 (5) :2596-2606.|[2]Zapata-Pérez R, et al. Reduced nicotinamide mononucleotide is a new and potent NAD+ precursor in mammalian cells and mice. FASEB J. 2021 Apr;35 (4) :e21456.